A Phase 2 interventional study of placebo and sildenafil in Benign Prostatic Hyperplasia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 2 sites in United States. Open to male participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-02-01.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Prostatic Hyperplasia with a site in United States — 29 open to participants now, 48 under way, none of them phase 3. Prostatic Hyperplasia · United States.
Among the 187 studies in Prostatic Hyperplasia with a site in United States, this one is the 119th largest by enrollment of the 150 interventional ones that give a count, is one of 3 that started in 2002, is one of 27 in phase 2, and was the 34th registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →29 of the 187 studies in Prostatic Hyperplasia with a site in United States are open now. Recruiting first, the newest first:
ALPFA Medical · Sites in United States
Ages 45+ · Men only
ProVerum Medical · Sites in United States
Ages 45+ · Men only
Zenflow, Inc. · Sites in United States
Ages 18+ · Men only
Northwestern University · Sites in United States
Ages 18–100 · Men only · Healthy volunteers
Northwestern University · Sites in United States
Ages 18–100 · Men only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 35 Years to 75 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 28 · Phase 4 16
First in 1988; this study’s year is marked. 3 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 83 across the 150 interventional studies, 208 across the 36 observational. Of the 119 that completed or were terminated, 58 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 187 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 3 studies filed under Prostatic Hyperplasia — fewer than ten, so there is no comparison to draw.
14 of the studies in Prostatic Hyperplasia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04288427Beth Israel Deaconess Medical Center5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy | 2026-12-30 |
| NCT05400980Prodeon Medical, IncExpander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath | 2027-01 |
| NCT06224218University of Illinois at ChicagoProstate Single Port & Laser Enucleation Comparison Trial | 2027-01-15 |
| NCT06560476Urotronic Inc.OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH | 2027-03-30 |
| NCT05898932Northwestern UniversityEnhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes | 2027-04 |
Add all 14 to your calendar (.ics) → With an account.
Among the 187 studies in Prostatic Hyperplasia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigate the effects of a single dose of sildenafil (100 mg) or placebo on blood pressure and pulse rate in subjects taking doxazosin for benign prostatic hyperplasia (BPH). To investigate the pharmacokinetics of doxazosin when co-administered with sildenafil 100 mg, and to investigate the safety and toleration of sildenafil 100 mg when co-administered with doxazosin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: sildenafil
Drug: placebo
placebo by mouth as a single dose
sildenafil 100 mg by mouth as a single dose
Pharmacodynamic parameters of blood pressure and pulse rate
Time frame: immediately predose, 15, 30, and 45 minutes and 1, 1.5, 2, 2.5, 3, 4, 6, and 8 hours postdose
Blood samples for doxazosin pharmacokinetic parameters
Time frame: time 0 (pre-dose), and at 1, 2, 3, 4, 6, and 8 hours post-dose
Safety and toleration of simultaneously co-administering sildenafil and doxazosin.
Time frame: continuous
The record gives a start of Nov 2002 and a completion of Jul 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →